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BackgroundHaematoma expansion leads to worse outcome in intracerebral haemorrhage(ICH). Tranexamic acid (TXA) is a promising haemostatic agent to preventhaematoma expansion and improve outcome after ICH.
MethodsTICH-2 is a multicentre prospective double blind randomised controlled trial,which recruited patients presenting within 8 hours of primary ICH to receiveintravenous TXA or placebo. Primary outcome is modified Rankin Scale at day 90and will be analysed using ordinal logistic regression, adjusted for minimisationcriteria. Secondary outcomes will be analysed using adjusted binary logisticregression and multiple linear regression; these include haematoma expansionat 24 hours, day 7 National Institute of Health Stroke Scale (NIHSS), day 90Barthel Index, quality of life, cognition and mood.
ResultsA total of 2325 patients were recruited between 14th March 2013 and 30thSeptember 2017, from 12 countries: United Kingdom (n= 1910), Italy, Georgia,Switzerland, Malaysia, Hungary, Poland, Ireland, Turkey, Sweden, Denmark andSpain. Randomisation characteristics included: age 68.9 (13.8) years; male 1301(56.0%); time from onset to randomisation 3.6 hours [2.6, 5.0]; NIHSS 13 (7.5);Glasgow coma scale 13.4 (2.1); systolic blood pressure 172.6 (27.2) mmHg;intraventricular haemorrhage 745 (32.0%) and prior antiplatelet use 610(26.2%).
ConclusionTICH-2 is the largest trial of TXA in spontaneous ICH and recruited over itsoriginal target of 2000 patients. The results will be available in May 2018 andwill inform whether TXA should be recommended for the treatment of acutespontaneous ICH.
